Development and preclinical evaluation of an alphavirus replicon vaccine for influenza
Authors:
- Todd TalaricoTTTodd Talarico
- Maureen MaughanMMMaureen Maughan
- Elizabeth A. ReapERElizabeth A. Reap
- Peter BerglundPBPeter Berglund
- Kurt I. KamrudKKKurt I. Kamrud
- Laura CoppLCLaura Copp
- Whitney LewisWLWhitney Lewis
- Chad CecilCCChad Cecil
- Pamela NorbergPNPamela Norberg
- Jordan WagnerJWJordan Wagner
- Aubrey WatsonAWAubrey Watson
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB ProteinsClinical and Vaccine Immunology, 2007
- Alphavirus replicon approach to promoterless analysis of IRES elementsVirology, 2007
- Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed HumansPLOS Medicine, 2007
- Intranasal vaccination with ISCOMATRIX® adjuvanted influenza vaccineVaccine, 2003
- Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral ProteinScience, 1993
- Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells.Journal of Experimental Medicine, 1991
- Cytotoxic T-Cell Immunity to InfluenzaNew England Journal of Medicine, 1983
- Evaluation of a Neuraminidase-Specific Influenza A Virus Vaccine in Children: Antibody Responses and Effects on Two Successive Outbreaks of Natural InfectionThe Journal of Infectious Diseases, 1979
- Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virusNature, 1978
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972